Affiliation:
1. All-Russian Centre for Emergency and Radiation Medicine n.a. A.M. Nikiforov
Abstract
We conducted a laboratory examination of 83 people after vaccination against the new coronavirus with the use of the ‘Gam-COVID-Vac’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya (Moscow, Russia), in order to determine the presence of post-vaccination class G antibodies to SARS-CoV-2. The reagent system ‘SARS-CoV-2-IgG – ELISA-BEST’ (Vector-Best Co., Novosibirsk, Russia) was used. According to the manufacturer, the reagent system detects a pool of class G immunoglobulins synthesized to all antigenic determinants of protein S, including the RBD domain, which ensures the specificity of this method for assessing the post-vaccination immune response. The study involved 36 men and 47 women, with an average age of 48.40 ± 1.15 years. An interim analysis of the blood serum of 51 participants 21 days after the first dose of the vaccine showed the presence of IgG antibodies to SARS-CoV-2 in 45 (88.24%) people. After 42 days, all 83 (100%) people were found to have IgG antibodies to SARS-CoV-2 virus. It is advisable to continue the study to assess the dynamics of the level of postvaccinal antibodies for 6 months.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference5 articles.
1. https://www.rosminzdrav.ru. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)», версия 10.
2. https://index.minfin.com.ua.
3. Kuvshinova I. N., Molodykh S. V., Livitskaya N. I. and others. Assessment of the quality of reagent kits OA “Vector Best” for the detection of antibodies to SARSCoV-2 using the Anti-SARS-CoV-2 verification panel (NIBSC, UK).
4. Denis Y. Logunov, Inna V. Dolzhikova, Olga V. Zubkova, Amir I. Tukhvatullin, Dmitry V. Shcheblyakov, et. al. (2021). Safety and efficacy of the vector heterologous vaccine COVID-19 based on rAd26 and rAd5: an interim analysis of a phase 3 randomized controlled trial in Russia. Russia. The Lancet. P. 397671–681. DOI: https://doi.org/10.1016/S0140–6736(21)00234–8.
5. Talha Khan Burki. (2020). The Russian vaccine for COVID-19. The Lancet Respiratory Medicine. 8, e85-e86
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献